Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IONIS-AGT-LRX in chronic heart failure with reduced ejection fraction
2020-005878-10Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing IONIS-AGT-LRX with Placebo (2 arms). Primary endpoint: Percent change in plasma angiotensinogen from baseline to Study Day 85. Started Mar 2021; status: completed.
02
Drugs
evazarsen
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2020-005878-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005878-10.